Authors
Latest:
Dr. Anasetti Discusses the Trade-offs of BMT and PBSCDr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC
Latest:
Dr. Lau on Controversies Surrounding Prostate Cancer ScreeningClayton S. Lau, MD, director, Urologic Oncology, director, Robotic Surgery, Prostate Cancer Surgery, interim chair of Urology, City of Hope, discusses the controversies surrounding prostate cancer screening. Lau spoke on this in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.
Latest:
Dr. Schmitt on a Novel Treatment Approach to Hodgkin LymphomaClemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.
Latest:
Patient-Derived Xenograft (PDX) Models as Avatars for Patient Response to TherapyThe promise of personalized medicine in cancer will only be met once physicians have both the arsenal of therapeutics they need and a more complete understanding of genomic tumor profiles.
Latest:
Dr. Hudis on Combating Obesity in Breast CancerClifford A. Hudis, MD, CEO, ASCO, discusses how oncologists should be helping patients with breast cancer overcome obesity.
Latest:
What Oncologists Need to Know About USP and the Recent ClarificationPatients with cancer across the country rely on community oncology practices to provide them with high-quality, coordinated cancer care.
Latest:
Preventing and Treating Bone Metastases in mCRPCBone metastases in metastatic castration-resistant prostate cancer can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.
Latest:
Colleen O'Leary Describes Chemotherapy SafetyColleen OLeary from James Cancer Hospital Describes Chemotherapy Safety Standards
Latest:
No Need to Wait for the Perfect Match-Cord Blood Is Saving Time and LivesThe perception that cord blood is an inferior source of stem cells is simply not accurate and may result in delays in lifesaving treatment for patients.
Latest:
Dr. Batlevi on the Role of Active Surveillance in Advanced-Stage Follicular LymphomaConnie L. Batlevi, MD, PhD, discusses the role of active surveillance in advanced-stage follicular lymphoma.
Latest:
10 Tips for Breast Cancer Screening and Early DetectionEarly detection offers the best chance for a cure.
Latest:
The Importance of Combination Immune Therapy in Orthotopic Murine GlioblastomaConnor Liu, medical student, Washington University School of Medicine, discusses the importance of combination immunotherapy in orthotopic murine glioblastoma.
Latest:
Mirvetuximab Soravtansine Associated With Improved HRQOL in FRα+ Ovarian CancerMirvetuximab soravtansine improved health-related quality of life in patients with FRα-positive, platinum-resistant ovarian cancer.
Latest:
Biology of Bone Metastases in Patients With mCRPCConor Lynch, PhD, an associate professor of Tumor Biology at Moffitt Cancer Center, discusses the biology of bone metastases in patients with castration-resistant prostate cancer.
Latest:
Dr. Lehman on 3D Mammography in Screening for Breast CancerConstance D. Lehman, MD, PhD, professor of radiology and chief of Breast Imaging in the Department of Radiology at Massachusetts General Hospital, discusses how 3D mammography has been an efficient and beneficial screening tool in the field of breast cancer.
Latest:
Merging Community Practices With an Academic Cancer CenterConsolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate CancerDespite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Latest:
Dr. Tam Discusses the Side Effect Profile of Duvelisib in CLLConstantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the side effect profile of duvelisib in patients with chronic lymphocytic leukemia (CLL).
Latest:
BTK Inhibitors in CLL: Second Generation Drugs and BeyondDr. Constantine Tam provides an overview of the current and emerging treatment landscape for chronic lymphocytic leukemia (CLL), with a focus on Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and the next generation of BTK inhibitors under development.
Latest:
Dr. Tam on Trials Investigating BGB-3111 in CLL and Waldenstrom's MacroglobulinemiaConstantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.
Latest:
Top 5 Contagion® News Articles for the Week of August 27, 2017Stay up-to-date on the latest infectious disease news by checking out this snapshot of our top 5 articles of the week.
Latest:
Sam Donaldson Hosts Roundtable on End-of-Life Care for Cancer PatientsThe National Comprehensive Cancer Network (NCCN) 15th Annual Meeting in March opened with a roundtable discussion on "Cancer Care at the End of Life: When is Enough Enough?"
Latest:
Dr Langer on Encorafenib Plus Binimetinib in BRAF V600E–Mutant NSCLCCorey J. Langer, MD, discusses findings from the ongoing phase 2 PHAROS trial in patients with non–small cell lung cancer harboring BRAF V600E mutations.
